Drug Trial Radar · NCT03085095
A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Jan 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,134
Actual
Start
Apr 18, 2017
Primary completion
Oct 25, 2019
Study completion Nov 26, 2021
Sponsor
- Lead sponsor
- Myovant Sciences GmbHIndustry
- Sponsor type
- Industry
- First posted
- Mar 21, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the efficacy and safety of relugolix 120 milligrams (mg) orally once daily for 48 weeks on maintaining serum testosterone suppression to castrate levels (\< 50 nanograms/deciliter \[ng/dL\]) in participants with androgen-sensitive advanced prostate cancer.
Conditions
- Prostate Cancer
Interventions
RelugolixDrug
Relugolix 120-mg tablet administered orally once daily following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1
Leuprolide AcetateDrug
Leuprolide acetate depot suspension, 22.5 mg (or 11.25 mg in Japan, Taiwan, and China), every 3 months by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sustained Castration RateTime frame: From Week 5 Day 1 (Day 29) to Week 49 Day 1 (Day 337)
Locations
162 sites in 22 countries. Site status is shown where the registry gives one.
Tucson
Tucson, Arizona
Orange
Orange, California
Denver
Denver, Colorado
Pompano Beach
Pompano Beach, Florida
Jeffersonville
Jeffersonville, Indiana
Des Moines
Des Moines, Iowa
Wichita
Wichita, Kansas
Baltimore
Baltimore, Maryland
Troy
Troy, Michigan
Omaha
Omaha, Nebraska
Las Vegas
Las Vegas, Nevada
Brick
Brick, New Jersey
Albuquerque
Albuquerque, New Mexico
Albany
Albany, New York
Garden City
Garden City, New York
Plainview
Plainview, New York
Poughkeepsie
Poughkeepsie, New York
Syracuse
Syracuse, New York
Durham
Durham, North Carolina
Greensboro
Greensboro, North Carolina
Cincinnati
Cincinnati, Ohio
Middleburg Heights
Middleburg Heights, Ohio
Oklahoma City
Oklahoma City, Oklahoma
Lancaster
Lancaster, Pennsylvania
Myrtle Beach
Myrtle Beach, South Carolina
Nashville
Nashville, Tennessee
San Antonio
San Antonio, Texas
Camperdown
Camperdown, New South Wales, Australia
Tweed Heads
Tweed Heads, New South Wales, Australia
Wahroonga
Wahroonga, New South Wales, Australia
Redcliffe
Redcliffe, Queensland, Australia
Southport
Southport, Queensland, Australia
Linz
Linz, Austria
Brussels
Brussels, Belgium
Kortrijk
Kortrijk, Belgium
Gent
Ghent, Oost-Vlaanderen, Belgium
Curitiba
Curitiba, Brazil
Itabuna
Itabuna, Estado de Bahia, Brazil
Salvador
Salvador, Estado de Bahia, Brazil
Salvador
Salvador, Estado de Bahia, Brazil
Showing 40 of 162 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.